Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
January 27, 2016 08:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
Recro Pharma to Present at NobleCon12 Investor Conference
January 14, 2016 13:19 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
January 06, 2016 07:00 ET
|
Societal CDMO, Inc.
IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported Company on Track to Initiate Pivotal Phase III in 1Q 2016 MALVERN, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) --...
Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
December 02, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
November 24, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma Reports Third Quarter 2015 Financial Results
November 13, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma to Participate in Upcoming Investor Conferences
November 12, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
Recro Pharma Provides Pipeline Update
October 26, 2015 08:00 ET
|
Societal CDMO, Inc.
IV Meloxicam Advancing to Phase III; Pivotal Trials Expected to Commence in First Quarter 2016
Company Shifts Focus of Dex-IN to Peri-Procedural Pain Indication
MALVERN, Pa., Oct. 26, 2015...
Recro Pharma Appoints Karen A. Flynn to Its Board of Directors
September 10, 2015 13:41 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...
Recro Pharma Announces Presentations at PAINWeek 2015
September 10, 2015 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...